AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03603886 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telemedicine Pain Management Intervention (waitlist group, intervention administered following 4-week waitlist period)
Description: Four week waitlist period during which participants receive treatment as usual. Following the waitlist period, participants will receive the telemedicine pain management intervention:~Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management.
Study NCT00585949 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Angioplasty
Description: This is a procedure by which the blood vessels of the heart are imaged with an insertion of a catheter in the groin and blocked arteries are opened.
Study NCT00585949 — intervention group
Intervention type: PROCEDURE
Intervention: Angiography
Description: Angiography is an imaging technique to see coronary blood vessels.
Study NCT01906931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable oxygen cylinder
Description: Portable oxygen cylinder at flow rate 5 Litres/min
Study NCT01906931 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable oxygen cylinder
Description: Portable oxygen cylinder at flow rate 5 Litres/min
Study NCT01112995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus
Description: 1 pill formulation to be given once a day for 4 weeks
Study NCT01112995 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill (placebo)
Description: placebo identical to the active product will be given
Study NCT02453594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study NCT00569972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched oral placebo for weeks 2-7.
Study NCT02329015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-informed Health and Wellness Program
Description: The HWP will be comprised of physical postures, breathing exercises, a period of sitting in stillness (meditation) and relaxation provided two times per week, 45 minutes per session, for the entire school year (Sept. - June).
Study NCT02329015 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Education Class
Description: Standard physical education
Study NCT03031912 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine
Description: The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.
Study NCT03031912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.
Study NCT05727358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Acceptance and Commitment Therapy
Description: G-ACT treatment in this study comprised 7 sessions of 45-60 minutes and was administered throughout the course of the 4-week long trial.
Study NCT04186962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: Simple cognitive task
Description: A memory reactivation cue followed by playing the computer game Tetris
Study NCT01532362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apricoxib
Description: As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
Study NCT01532362 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apricoxib
Description: As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
Study NCT01383681 — intervention group
Intervention type: OTHER
Intervention: No treatment
Description: There was no treatment in this study.
Study NCT01323569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.
Study NCT01323569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Sativex dose level 2: 21.6 mg THC/20 mg CBD (8 sprays) + 8 placebo sprays + 4 placebo capsules
Study NCT01323569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Sativex dose level 3: 43.2 mg THC/40 mg CBD (16 sprays) + 4 placebo capsules
Study NCT01323569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 16 placebo sprays and 4 placebo capsules
Study NCT01323569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marinol
Description: Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays
Study NCT01323569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marinol
Description: Marinol dose level 2: 40 mg THC (4 marinol capsules) + 16 placebo sprays
Study NCT00634647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satraplatin
Description: 80 mg/m\^2 days 1-5 of every 35 day cycle
Study NCT00634647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 5 mg twice daily every 35 days
Study NCT03747484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR
Description: Given IV
Study NCT03747484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT03747484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03747484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon Gamma-1b
Description: Given SC
Study NCT02309385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8% Dexamethasone Sodium Phosphate - Visulex
Study NCT02309385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% Dexamethasone Sodium Phosphate - Visulex
Study NCT04121169 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IM-01
Description: Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile
Study NCT02309385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate (1%) Eye Drops
Study NCT02212730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Pre-Resection
Description: 200 mg administered by IV, once every 3-week cycle for a maximum of 2 cycles
Study NCT02212730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Standard of care surgical resection of RCC tumor
Study NCT02212730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Post-Resection
Description: 200 mg administered by IV, once every 3-week cycle for a maximum of 17 cycles
Study NCT04031885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT04031885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered IM
Study NCT04031885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy
Description: Standard chemotherapy of physician's choice administered according to product label.
Study NCT02621983 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
Study NCT02621983 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance and Stretching
Description: Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
Study NCT02366481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.
Study NCT02366481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)
Description: One 90-mcg vitamin K2 softgel capsules (containing no vitamin K2) and one placebo softgel capsule everyday for 8 weeks.
Study NCT02366481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)
Description: Two 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
Study NCT00587587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apligraf
Description: Application at Day 0, potential re-application at Week 4
Study NCT00587587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dressing regimen
Description: A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
Study NCT01162005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: dosage : 0.1-0.2 mg/kg/day divided two target trough level : 5 - 10 ng/mL Total duration (tacrolimus) : 1 year
Study NCT00854087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fuzheng Huayu
Description: The subjects will be taking 2 tablets three times a day for 48 weeks.
Study NCT00854087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will be taking 2 tablets three times a day for 48 weeks.
Study NCT02879097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CBT124
Description: Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
Study NCT02879097 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced Avastin®
Description: Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
Study NCT02879097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
Study NCT02879097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
Study NCT02879097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
Study NCT02879097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
Study NCT00111644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: 1000mg iv daily
Study NCT00111644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-lactam
Description: 750mg iv q 23h for 3-14 days
Study NCT00111644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-lactam
Description: 1500mg iv q 12h for 3-14 days
Study NCT04011059 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Wharton's jelly-derived mesenchymal cells
Description: Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.
Study NCT04011059 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Wharton's jelly-derived mesenchymal cells
Description: Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.
Study NCT02866617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model
Study NCT03592472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
Study NCT03592472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pazopanib
Description: All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
Study NCT03592472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abexinostat
Description: The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
Study NCT03592472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
Study NCT02923375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymoangioblast-derived mesenchymal stem cells
Description: The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.
Study NCT04667819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate
Description: We usage a special type of anterior eye drug delivery system to conduct the transmission of sodium hyaluronate in dry eye patients.
Study NCT04163549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe at Home
Description: Discussion-based intervention
Study NCT03285646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Description: Subcutaneous (SC) every 4 weeks (Q4W)
Study NCT03285646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) every 4 weeks (Q4W)
Study NCT03623828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe
Description: Product administered using an external continuous subcutaneous infusion pump.
Study NCT04709237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A control lens
Description: Participants were randomized to wear omafilcon A control soft contact lens for 10 days.
Study NCT04709237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A test lens 1
Description: Participants were randomized to wear omafilcon A test soft contact lens 1 for 10 days.
Study NCT04709237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A test lens 2
Description: Participants were randomized to wear omafilcon A test soft contact lens 2 for 10 days.
Study NCT02237105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy
Study NCT03847181 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban at a dose of 15 or 20 mg once daily
Study NCT03847181 — intervention group
Intervention type: DRUG
Intervention: Apixaban (Eliquis)
Description: Apixaban at a dose of 2.5 or 5 mg twice daily
Study NCT03847181 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin dose as prescribed by medical practitioner
Study NCT04048460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delivery of hearing healthcare through eAudiology application
Description: Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
Study NCT03724422 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: A dose of 500cGy will be delivered in 1 fraction to the isocenter. Radiation will be administered no later than 72 hours postoperatively
Study NCT03285373 — intervention group
Intervention type: DRUG
Intervention: NOAC
Description: New Oral Anticoagulant
Study NCT01344057 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seasonal Influenza Vaccine
Description: This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
Study NCT01662869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoruracil
Description: Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m\^2) IV bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
Study NCT01662869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluoruracil
Description: Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m\^2) IV bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
Study NCT01662869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
Study NCT03284957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Pharmaceutical form: tablet
Study NCT01534052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral
Study NCT01662869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folinic acid
Description: Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
Study NCT01662869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Participants will receive onartuzumab 10 mg/kg IV infusion on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.